Basic Information
| LncRNA/CircRNA Name | TP73-AS1 |
| Synonyms | NA |
| Region | NA |
| Ensemble | ENSG00000227372 |
| Refseq | NR_033708 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | apoptosis | Drug | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | cholangiocarcinoma |
| ICD-0-3 | NA |
| Methods | qPCR, in vitro knockdown |
| Sample | cholangiocarcinoma tissues, cell lines (HCCC-9810 and RBE) |
| Expression Pattern | up-regulated |
| Function Description | The results illustrated that TP73-AS1 transcription is enhanced in both CCA tissue samples and cell lines, and this upregulation is closely associated with larger tumor size (p=0.008) and advanced TNM stage (p=0.026) in patients with CCA. For the part of functional assays, silencing of TP73-AS1 could attenuate CCA cell growth both in vitro and in vivo. Additionally, silencing of TP73-AS1 facilitates apoptosis via activating caspase-3 and caspase-9. Importantly, TP73-AS1 expression did not affect HIBEC cell growth and apoptosis. Moreover, TP73-AS1 could also facilitate migration and invasion potential of CCA cells. |
| Pubmed ID | 29966969 |
| Year | 2018 |
| Title | Enhanced Expression of lncRNA TP73-AS1 Predicts Adverse Phenotypes for Cholangiocarcinoma and Exerts Oncogenic Properties in Vitro and in Vivo |
External Links
| Links for TP73-AS1 | GenBank HGNC NONCODE |
| Links for cholangiocarcinoma | OMIM COSMIC |